Replies to post #1313 on Vascular Biogenics Ltd (VBLT)

[gr8db8]

DSMC can stop the trial early due to good/bad reasons. In this case, if it were to stop it would be for a good reason.

However, I don't think this trial will stop early. VB-111 may be an improvement but not enough to stop the trial early so that patients on the Avastin arm also get VB-111.

This week is cool. We're getting the DSMC decision - hopefully good. Then it's on to the final topline data.